Fixing Healthcare Podcast

For the next two weeks, Fixing Healthcare hosts Jeremy Corr and Dr. Robert Pearl will be replaying past episodes of Diving Deep while Dr. Pearl travels and keynotes events around the world. But these aren’t random reruns. They were selected for a reason: to highlight just how quickly technology is advancing and how slowly healthcare is adapting. This week’s flashback revisits a July 2024 conversation recorded shortly after OpenAI released GPT-4o, a major leap forward in generative AI at the time. Less than two years later, the pace of change is striking. Capabilities that once felt groundbreaking now seem primitive compared to what today’s AI tools can accomplish for patients, physicians and healthcare organizations. At the same time, the episode’s broader themes remain remarkably current. Dr. Pearl and Jeremy discuss the future role of generative AI in medicine, how these tools could improve diagnosis and patient monitoring and why healthcare institutions often struggle to embrace transformative technology quickly. The episode also examines another issue that remains unresolved today: the high cost of GLP-1 medications like Wegovy and Ozempic. Dr. Pearl explains why these highly effective obesity treatments remain financially out of reach for many Americans despite growing demand and expanding clinical use. Revisiting this conversation now offers a useful reminder: technology can advance extraordinarily fast, but healthcare systems, incentives and policies often lag far behind. Helpful links:  OpenAI’s Rule-Shattering GPT-4o Update Will Be Lifesaving, Too (Forbes) Wegovy And Ozempic Are Overpriced By 400-500% — Here’s A Quick Solution (Forbes) Monthly Musings on American Healthcare (Robert Pearl’s newsletter) * * * Dr. Robert Pearl is the author of “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine.” Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post FHC #214: Revisiting GLP-1 prices and ChatGPT’s early leap forward appeared first on Fixing Healthcare.

They challenge myths about aging and highlight new data showing many older adults can improve function. They debunk quick-fix longevity trends like supplements and peptides. They argue prevention should start earlier, especially LDL screening. They outline redesigns to cut healthcare costs by subtracting inefficiency, scaling outpatient care, using AI and centralized home-based care.

In this week’s episode of Medicine: The Truth, hosts Jeremy Corr and Dr. Robert Pearl probe the facts beneath healthcare biggest headlines. Today’s show features an in-depth look at sweeping federal budget cuts, the expanding (and often misunderstood) impact of GLP-1 medications and what’s destabilizing health coverage. The conversation opens with a stark warning. Dr. Pearl reviews the president’s proposed 2027 budget, which includes a $15.8 billion reduction in healthcare spending. He explains why cuts to Medicaid, NIH research and global health programs could have consequences that extend far beyond the next fiscal year, potentially slowing innovation, increasing patient risk and shifting costs to states and families. From there, the episode turns to one of the most asked-about topics from listeners: GLP-1 weight-loss drugs. While these medications clearly produce meaningful weight loss and improve outcomes in conditions tied to obesity, Dr. Pearl cautions that many of the broader health claims attributed to them may simply reflect the benefits of weight loss itself, not unique properties of the drugs. Throughout the episode, an underlying truth: scientific progress continues but policy decisions, pricing dynamics and system design may limit who benefits (and at what cost). Here are the other major storylines from episode 106: Federal health cuts threaten long-term progress: The proposed budget reduces overall healthcare funding by 12.5%, cuts NIH support by $5 billion and consolidates public health agencies. Global health funding drops sharply: International health spending is being cut nearly in half, while continued withdrawal from the World Health Organization leaves the U.S. more vulnerable to future pandemics. CDC leadership signals a policy shift: The nomination of Dr. Erica Schwartz as permanent CDC director suggests a move back toward a more traditional, science-driven approach to vaccines. RFK Jr. softens vaccine stance amid political pressure: In congressional testimony, the HHS secretary publicly acknowledged the safety and effectiveness of the measles vaccine. GLP-1 drugs deliver clear weight loss and major benefits: Studies show 10-20% weight reduction, along with approximately 20% improvements in kidney and cardiovascular outcomes. Many GLP-1 “breakthroughs” may reflect weight loss alone: Evidence linking these drugs to reduced cancer risk, improved cognition or lower addiction rates remains fuzzy at best. Exercise rivals the impact of breakthrough drugs: A large study shows vigorous physical activity reduces risks of dementia, diabetes, cardiovascular disease and death at levels comparable to or greater than GLP-1 outcomes. Stress does not directly cause cancer: Pearl explains that while many Americans believe stress leads to cancer, the real risk comes from behavioral responses such as increased smoking and alcohol use. Concierge medicine expands access for some: Patients who can afford annual fees gain faster access and more time with physicians, but the model reduces availability for others. China rapidly closes the drug development gap: New data show China’s share of global pharmaceutical research rising to over 32%, nearly matching the United States. Exchange coverage declines and risk pools worsen: Millions may lose insurance due to subsidy changes, premium nonpayment and shifts to high-deductible plans. Drug prices continue to rise despite reform efforts: Under the TrumpRx program, lower prices on select drugs have been offset by increases elsewhere, with new medications averaging $353,000 annually. Robotics and AI may arrive faster than expected: A dramatic improvement in robot race performance leads Dr. Pearl to revise his estimate for clinical adoption of robotic procedures. Tune in for more fact-based analysis and practical perspective on the healthcare policies, technologies and trends shaping medicine today. * * * Dr. Robert Pearl is the author of “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine” about the impact of AI on the future of medicine. Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post MTT #106: Trump’s 2027 budget & the other threats to U.S. healthcare appeared first on Fixing Healthcare.

OpenAI didn’t need to convince patients to try generative AI. According to Dr. Nate Gross, Health of Health at OpenAI, 230 million people already use ChatGPT each week to interpret lab results, prepare for visits, understand diagnoses or ask health-related questions they didn’t have time (or confidence) to raise in the exam room. But what about clinicians? On this episode of Fixing Healthcare, Dr. Robert Pearl and Jeremy Corr speak with Dr. Gross, who previously co-founded Doximity and Rock Health, about OpenAI’s latest step: the release of ChatGPT for Clinicians, a new offering that brings healthcare-specific AI tools directly to individual providers, without requiring access through a large health system contract. In other words, the same capabilities previously limited to enterprise deployments are now being placed in the hands of front-line clinicians. But as Dr. Gross makes clear in this timely interview, the story of AI in medicine is much bigger than a single product. It’s about how generative AI is beginning to reshape healthcare across three fronts at once: patients, clinicians and health systems. Key highlights include: Patients are already using AI at massive scale. Gross notes that roughly 40 million people turn to ChatGPT for help outside the clinical setting each day, often at night or between visits. They’re using it to understand symptoms, interpret medical advice and navigate a fragmented healthcare system. Clinicians don’t want another AI tool. They want less friction. From documentation and inbox overload to prior authorizations and evidence review, physicians are looking for ways to reduce administrative burden and focus on patient care. Generative AI, when applied well, can help “sweep the floor” of repetitive work. ChatGPT for clinicians expands access beyond health systems. Previously, OpenAI’s healthcare tools were deployed through enterprise environments. This new release allows individual physicians, nurses and other providers to access clinical-grade AI tools directly, regardless of where they practice. Healthcare is shifting from “if” to “how” with AI. Health systems are no longer debating whether generative AI is real or ready. Instead, leaders are focused on how to deploy it safely, securely and in ways that improve care without introducing new risks. Fragmentation remains healthcare’s biggest challenge. Patients often act as the “integration layer” between specialists, systems and settings. Gross sees AI as a potential tool to help synthesize information, coordinate care and improve communication across the system. The future of care extends beyond the clinic. From chronic disease management to hospital-at-home models, AI tools could help patients better understand and follow care plans in their daily lives, improving outcomes between visits, not just during them. Medical education and research are also evolving. Gross highlights OpenAI’s work to personalize learning for clinicians and accelerate scientific discovery, including new AI models designed to support biology, genomics and drug development. Skepticism still matters. Despite the momentum, Gross emphasizes the importance of validation, clinician oversight and continuous feedback to ensure these tools are used responsibly and effectively. Dr. Pearl shares his thoughts. Pearl embraces Gross’s three-part framework of patients, clinicians and health systems, but believes the greatest opportunity lies in transforming how care is delivered. From chronic disease management to AI-powered care in the home, he emphasizes that the real impact will come not from administrative gains, but from improving outcomes at scale—provided healthcare moves fast enough to keep today’s challenges from becoming tomorrow’s crises. There’s much more in this conversation, including how healthcare leaders should think about AI in long-term planning and a deeper dive into the biggest opportunities that lie ahead. Tune in to hear what physicians, patients and health systems should expect from the next chapter of medicine. * * * Dr. Robert Pearl is the bestselling author of ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine. Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post FHC #212: OpenAI’s Nate Gross on ChatGPT’s next big move in healthcare appeared first on Fixing Healthcare.

In this Unfiltered episode of Fixing Healthcare, Drs. Robert Pearl and Jonathan Fisher join cohost Jeremy Corr to explore one of medicine’s least discussed forces: how professional culture gradually reshapes physician identity. The conversation begins with relationships using an unlikely touchpoint: FX’s Love Story: John F. Kennedy Jr. & Carolyn Bessette. Using marriage, friendship, doctor-patient dynamics and colleague trust as a launching point, Pearl and Fisher examine how stress, burnout and emotional spillover affect the people clinicians care about both at home and at work. Fisher draws on his retreat work with healthcare professionals to explain why slowing down, reconnecting socially and stepping outside the clinical environment are often prerequisites for restoring empathy and perspective. Midway through, the discussion deepens into the powerful theme introduced through the popular SHOWTIME show Billions: the way workplace environments subtly redefine who people become over time. In medicine, that process can begin as early as the first weeks of training. Small acts of conformity, repeated decisions at the edge of one’s values and cultural reinforcement gradually shift how physicians think, behave and ultimately define themselves. The result is a larger question that runs through the entire episode: How do clinicians preserve their humanity, relationships and deepest values inside a system that often rewards speed, hierarchy and productivity over reflection and connection? Finally, Jeremy’s closing question on behalf of patients helps to push both physicians to confront a national reality: when specialist access takes months, compassion must be communicated quickly and system design must improve the patient experience itself. For listeners who connected with Jonathan’s discussion of physician recovery, reflection and emotional renewal, check out his upcoming ASPIRE physician retreat, a CME-accredited experience for healthcare professionals, taking place June 12-14 in Boone, North Carolina. Use code ASPIRE15 for 15% off registration. For more unfiltered conversation, listen to the full episode and explore these related resources: ‘Just One Heart’ (Jonathan Fisher’s newest book) ‘ChatGPT, MD’ (Robert Pearl’s newest book) Monthly Musings on American Healthcare (Robert Pearl’s newsletter) * * * Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple Podcasts or wherever you find podcasts. Join the conversation or suggest a guest by following the show on Twitter and LinkedIn. The post FHC #211: How medical culture slowly reshapes physician identity appeared first on Fixing Healthcare.

They discuss how rising healthcare jobs may signal a productivity crisis rather than strength. They explore generative AI use cases like continuous chronic disease monitoring, hospital-at-home care, and earlier detection of inpatient decline. They introduce vibe coding — plain-English tools clinicians can build to create personalized apps for pre-op prep, postop monitoring, and daily disease tracking.

New research shows many seniors can improve physically and cognitively over time. Guidance pushes earlier, long-term LDL management to prevent future heart attacks and strokes. Common supplements fail to lower LDL in trials, underscoring statins and lifestyle. Alarming trends around rising medical debt, drug unaffordability and declining vaccine trust threaten access. CMS moves to phase out faxing to modernize healthcare communication.

Dr. John Whyte, CEO of the American Medical Association and former FDA/CMS leader, shares what physicians and patients are telling him now. He tackles concerns about prior authorization and payment incentives. He explores Medicaid changes risking children’s coverage. He discusses AI and digital health as tools clinicians must steer, plus payment barriers to adopting effective tech.

Jonathan Fisher, cardiologist, mindfulness expert, and author, explains why empathy alone cannot carry healthcare leadership. He explores the need for strategic thinking, operational discipline, and business skills in medicine. Short segments cover burnout’s impact on strategy, why primary care is undervalued, training clinicians in finance and execution, and how attention and flow affect performance under pressure.

They discuss three looming healthcare threats: the coming affordability cliff, the chronic disease crisis, and the risk of training clinicians for the wrong future. Conversation turns to where generative AI stands now and how it could help with chronic care, reduce medical errors, and automate intake and treatment planning. Cultural barriers and early real-world pilots get highlighted as decisive next steps.